PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative EBIT growth while CRVO is at 54.27%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-63.84%
Negative operating income growth while CRVO is at 54.27%. Joel Greenblatt would press for urgent turnaround measures.
-88.24%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-87.91%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-87.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-63.84%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
OCF/share CAGR of 53.61% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
53.61%
OCF/share CAGR of 53.61% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
53.61%
3Y OCF/share CAGR of 53.61% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
35.25%
10Y net income/share CAGR of 35.25% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
35.25%
Below 50% of CRVO's 81.24%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
35.25%
Below 50% of CRVO's 81.24%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Asset growth of 1280.26% while CRVO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
-28.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
50.95%
Debt growth of 50.95% while CRVO is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
47.25%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.